Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations

Abstract

TO THE EDITOR: Allogeneic hematopoietic stem-cell transplantation (ASCT) is curative treatment for patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), who otherwise have dismal outcomes.[1][1][⇓][2][⇓][3]-[4][4] The TP53 gene is located in the 17p13